The $2 Billion Question: Is Enveda's AI Discovering New Medicine or Just Indexing Nature?
AI-generated image · Bay Street Wire
Opinion: With a massive valuation jump and a Series E windfall, Enveda is betting that AI can unlock nature's secrets—but the real test is whether these candidates can survive clinical trials.
In the current biotech gold rush, valuation is often treated as a proxy for validation. But as a health tech columnist, I've learned that the distance between a venture capital milestone and an FDA approval is a chasm filled with failed candidates. The latest example of this tension is Enveda.
As TechCrunch first reported, Enveda recently secured $311 million in a Series E funding round. This investment, led by Catalio Capital Management with participation from Iconiq and other unnamed investors, has pushed the company's valuation to $2 billion—doubling the valuation it held just 12 months ago.
Founded in 2019 by Viswa Colluru, a former early employee of Recursion Pharmaceuticals, Enveda leverages AI to discover potential medicines hidden within plants and microbes rather than synthesizing drugs from scratch. It is, in essence, a high-tech scavenger hunt for the natural world's most potent compounds.
However, I find the $2 billion price tag provocative. The central question is whether Enveda's AI is actually producing novel, clinically viable results, or if it is simply acting as a high-priced digital library for compounds that nature already created.
We must start with the industry-wide reality: as TechCrunch points out, AI has yet to produce a single FDA-approved drug. This is the critical bottleneck. While scanning biological data at scale is an impressive engineering feat, the biological reality of the human body is far less predictable than a dataset.
Enveda is currently attempting to bridge this gap. The company is testing several drug candidates in human clinical trials, including a treatment for severe skin conditions and another designed to help patients maintain weight loss after they stop using GLP-1 medications.
If Enveda's AI is merely identifying known chemical structures, the $2 billion valuation is an exercise in exuberance. For the company to justify its price, its AI must do more than catalog; it must predict efficacy and safety in a way that fundamentally reduces the failure rate of clinical trials. Until these candidates clear the regulatory hurdles of the FDA, Enveda remains a high-stakes bet.